Separate terms with OR to return results that match either term.
 
Clear All
716 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year (Ascending) CMS Effective Date CMS Discontinuation Date Status
J9064 Cabazitaxel (Sandoz) Cabazitaxel 1mg Chemotherapy Antimitotic Agent Taxane No 2023 Aug. 28, 2023 In Use
J9345 Retifanlimab-dlwr Zynyz 1mg Immunotherapy Checkpoint Inhibitor PD-1 No 2023 Aug. 28, 2023 In Use
C9163 Talquetamab Talvey 0.25mg Immunotherapy T Cell Receptor (TCR) GPRC5D, CD3 No 2023 Dec. 7, 2023 April 17, 2024 No Longer Used
C9165 Elranatamab-bcmm Elrexfio 1mg Immunotherapy Monoclonal Antibody BCMA, CD3 No 2023 Dec. 7, 2023 April 17, 2024 No Longer Used
J9052 Carmustine (Accord) Carmustine 100mg Chemotherapy Alkylating Agent Nitrosurea No 2022 Dec. 7, 2023 In Use
J9072 Cyclophosphamide (Dr Reddy's) Cyclophosphamide 5mg Chemotherapy Alkylating Agent Nitrogen Mustard No 2023 Dec. 7, 2023 In Use
J9172 Docetaxel (Ingenus) Docetaxel 1mg Chemotherapy Antimitotic Agent Taxane No 2017 Dec. 7, 2023 In Use
J9255 Methotrexate (Accord) Methotrexate 50mg Chemotherapy Antimetabolite Folic Acid Analog No 2014 Dec. 7, 2023 In Use
J9258 Paclitaxel (Teva) Paclitaxel 1mg Chemotherapy Antimitotic Agent Taxane No 2016 Dec. 7, 2023 In Use
J9286 Glofitamab-gxbm Columvi 2.5mg Immunotherapy Monoclonal Antibody CD20, CD3 No 2023 Dec. 7, 2023 In Use
J9321 Epcoritamab-bysp Epkinly 0.16mg Immunotherapy Monoclonal Antibody CD20, CD3 No 2023 Dec. 7, 2023 In Use
J9324 Pemetrexed disodium Pemrydi-rtu 10mg Chemotherapy Antimetabolite Folic Acid Analog No 2023 Dec. 7, 2023 In Use
Adagrasib Krazati 200mg Immunotherapy RAS Inhibitor KrAS G12C Yes 2022 In Use
Asciminib Scemblix 20mg,40mg Chemotherapy Tyrosine Kinase Inhibitor ABL/BCR-ABL1 Yes 2021 In Use
Futibatinib Lytgobi 4mg Chemotherapy Tyrosine Kinase Inhibitor FGFR Yes 2023 In Use
Infigratinib Truseltiq Multiple Chemotherapy Tyrosine Kinase Inhibitor FGFR Yes 2021 In Use
Maribavir Livtencity 200mg Ancillary Therapy Miscellaneous Agent CMV Antiviral Yes 2021 In Use
Momelotinib Ojjaara Multiple Chemotherapy Enzyme Inhibitor JAK 1/2 Yes 2023 In Use
Mobocertinib Exkivity 40mg Chemotherapy Tyrosine Kinase Inhibitor EGFR Yes 2021 In Use
Niraparib and Abiraterone Akeega Multiple Chemotherapy Androgen Receptor Inhibitor, Enzyme Inhibitor CYP 17, PARP Yes 2023 In Use
Olutasidenib Rezlidhia 150mg Chemotherapy Enzyme Inhibitor IDH1 Yes 2022 In Use
Olutasidenib Rezlidhia 150mg Chemotherapy Enzyme Inhibitor IDH1 Yes 2022 In Use
Pacritinib Vonjo 100mg Chemotherapy Tyrosine Kinase Inhibitor JAK2, FLT3 Yes 2022 In Use
NA Pirtobrutinib Jaypirca Multiple Chemotherapy Tyrosine Kinase Inhibitor BTK Yes 2023 In Use
NA Purixan Purixan 20mg Chemotherapy Antimetabolite Purine Yes 2014 In Use

Found 716 results in 2 milliseconds — Export these results

The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.